Stockreport

resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update

RESTORBIO  (TORC) 
Last restorbio earnings: 3/12 07:30 am Check Earnings Report
PDF -- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cer [Read more]